Loading...
•
Jun 30, 2021
EyePoint Pharmaceuticals Q2 2021 Earnings Report
EyePoint Pharmaceuticals' Q2 2021 financial results were announced, highlighting a 136% increase in net product revenues compared to Q2 2020 and positive safety data from the EYP-1901 DAVIO trial.
Key Takeaways
EyePoint Pharmaceuticals reported a strong second quarter, marked by significant progress in the Phase 1 DAVIO trial for EYP-1901 and a substantial increase in net product revenue, driven by growing customer demand for DEXYCU and YUTIQ.
Net product revenues increased by 136% to $8.7 million compared to Q2 2020.
Positive 30-day safety data was reported for all cohorts in the DAVIO trial of EYP-1901 for wet AMD.
Patient enrollment was completed in the Phase 1 clinical trial of EYP-1901.
DEXYCU achieved an all-time high in unit demand, with approximately 10,900 units, a 404% increase from Q2 2020.
Revenue by Segment
Forward Guidance
EyePoint Pharmaceuticals expects its cash on hand and anticipated net cash inflows from product sales to fund current and planned operations through the end of 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...